Insider Transactions in Q4 2023 at Eye Point Pharmaceuticals, Inc. (EYPT)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2023
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,458
-5.37%
|
$29,160
$20.0 P/Share
|
|
Dec 13
2023
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,458
+5.09%
|
$14,580
$10.13 P/Share
|
|
Dec 08
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
588,235
+8.88%
|
$9,999,995
$17.0 P/Share
|
|
Dec 06
2023
|
Therapeutics Ocumension Director |
SELL
Open market or private sale
|
Direct |
266,242
-11.69%
|
$4,792,356
$18.41 P/Share
|
|
Dec 06
2023
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
266,242
-11.69%
|
$4,792,356
$18.41 P/Share
|
|
Dec 05
2023
|
Therapeutics Ocumension Director |
SELL
Open market or private sale
|
Direct |
733,758
-24.37%
|
$13,941,402
$19.91 P/Share
|
|
Dec 05
2023
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
733,758
-24.37%
|
$13,941,402
$19.91 P/Share
|
|
Dec 04
2023
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,625
-54.37%
|
$673,750
$22.0 P/Share
|
|
Dec 04
2023
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,625
+35.22%
|
$306,250
$10.13 P/Share
|
|
Dec 04
2023
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
SELL
Open market or private sale
|
Direct |
45,000
-89.39%
|
$990,000
$22.0 P/Share
|
|
Dec 04
2023
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+47.2%
|
$540,000
$12.62 P/Share
|
|
Dec 04
2023
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
20,000
-10.5%
|
$400,000
$20.76 P/Share
|
|
Dec 04
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
1,919,057
+2.16%
|
$49,895,482
$26.82 P/Share
|